Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 163 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Adding Relacorilant To Nab-paclitaxel Prolongs Survival Compared with a Weekly Taxane... June 23, 2025 ¿Qué son los biosimilares para el tratamiento del cáncer? November 30, 2021 Cancer-impacted mother becomes Times Square billboard to help child come across... July 21, 2023 Merging the Histologic and Molecular Data Into an Integrated Score Significantly... October 11, 2021 Load more HOT NEWS Targeted Therapy, Driven by Comprehensive Genomic Profiling and Molecular Tumour Board,... RNF43 Mutations Warrant Further Validation for Potential to Prioritise Anti-EGFR/BRAF Combinations... Pharmacokinetically Guided Dose Optimisation of Oral Targeted Therapies Reduces the Proportion... Bra Straps with Disappearing Message Remind Women to Check Their Breasts...
